Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trialYu Pengfei, Xiangdong Cheng, Jieer Ying et al.|Journal of Clinical Oncology|2023Cited by 1
Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.Yu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2023Cited by 0